Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
AKBA's Cash to Debt is ranked higher than
70% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. AKBA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AKBA' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 12424.6
Current: No Debt
N/A
12424.6
Interest Coverage No Debt
AKBA's Interest Coverage is ranked lower than
60% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AKBA' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
Z-Score: 8.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -42.17
AKBA's ROE (%) is ranked lower than
58% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. AKBA: -42.17 )
Ranked among companies with meaningful ROE (%) only.
AKBA' s ROE (%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -42.17
ROA (%) -39.41
AKBA's ROA (%) is ranked lower than
61% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. AKBA: -39.41 )
Ranked among companies with meaningful ROA (%) only.
AKBA' s ROA (%) Range Over the Past 10 Years
Min: -71.35  Med: -61.10 Max: -50.85
Current: -39.41
-71.35
-50.85
ROC (Joel Greenblatt) (%) -15350.83
AKBA's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. AKBA: -15350.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AKBA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -106220  Med: -68918.34 Max: -31616.67
Current: -15350.83
-106220
-31616.67
» AKBA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

AKBA Guru Trades in

Q2 2015

AKBA Guru Trades in Q2 2015

Jim Simons 381,239 sh (New)
» More
Q3 2015

AKBA Guru Trades in Q3 2015

Jim Simons 110,700 sh (-70.96%)
» More
Q4 2015

AKBA Guru Trades in Q4 2015

Jim Simons 109,200 sh (-1.36%)
» More
» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 36.50
AKBA's Forward P/E is ranked lower than
84% of the 342 Companies
in the Global Biotechnology industry.

( Industry Median: 16.21 vs. AKBA: 36.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.58
AKBA's P/B is ranked higher than
72% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. AKBA: 1.58 )
Ranked among companies with meaningful P/B only.
AKBA' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 9.5
Current: 1.58
0
9.5
Current Ratio 11.21
AKBA's Current Ratio is ranked higher than
78% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. AKBA: 11.21 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s Current Ratio Range Over the Past 10 Years
Min: 8.57  Med: 17.21 Max: 26.43
Current: 11.21
8.57
26.43
Quick Ratio 11.21
AKBA's Quick Ratio is ranked higher than
79% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AKBA: 11.21 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s Quick Ratio Range Over the Past 10 Years
Min: 8.57  Med: 17.21 Max: 26.43
Current: 11.21
8.57
26.43

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.53
AKBA's Price/Net Cash is ranked higher than
87% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: 5.67 vs. AKBA: 1.53 )
Ranked among companies with meaningful Price/Net Cash only.
AKBA' s Price/Net Cash Range Over the Past 10 Years
Min: 2.02  Med: 2.49 Max: 4.71
Current: 1.53
2.02
4.71
Price/Net Current Asset Value 1.51
AKBA's Price/Net Current Asset Value is ranked higher than
87% of the 883 Companies
in the Global Biotechnology industry.

( Industry Median: 5.05 vs. AKBA: 1.51 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AKBA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.99  Med: 2.43 Max: 4.65
Current: 1.51
1.99
4.65
Price/Tangible Book 1.51
AKBA's Price/Tangible Book is ranked higher than
83% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. AKBA: 1.51 )
Ranked among companies with meaningful Price/Tangible Book only.
AKBA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.98  Med: 2.40 Max: 4.63
Current: 1.51
1.98
4.63
Earnings Yield (Greenblatt) (%) -70.06
AKBA's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. AKBA: -70.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AKBA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -113.4  Med: 0.00 Max: 0
Current: -70.06
-113.4
0

More Statistics

EPS $ -2.13
Short Percentage of Float19.33%
52-Week Range $5.91 - 14.20
Shares Outstanding(Mil)30.63

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 6 38 44 5
EPS($) -2.20 -2.40 -3.08 -4.52
EPS without NRI($) -2.20 -2.40 -3.08 -4.52

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:AX9.Germany,
Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.
» More Articles for AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
Akebia to Present at the 18th Annual BIO CEO & Investor Conference Feb 01 2016
Akebia to Present at the 18th Annual BIO CEO & Investor Conference Feb 01 2016
Facebook Gets PT Hike; eBay, Apple Chip Supplier InvenSense Cut Jan 28 2016
Coverage initiated on Akebia Therapeutics by Credit Suisse Jan 21 2016
Smart Money Highlights Oversold Stocks in Small Cap Biotechs Jan 19 2016
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock Jan 14 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jan 12 2016
Biotechnology Equity Movers and Shakers -- Agenus, Xenoport, Akebia Therapeutics, and Northwest... Jan 11 2016
Several Stocks That Look Prime For A Short Squeeze Jan 07 2016
​What’s causing biotech stocks to go into a free-fall: It’s not just China Jan 07 2016
Akebia Therapeutics Slumps: AKBA Falls 10.9% in Session Jan 07 2016
Akebia Prices Public Offering of Common Stock Jan 06 2016
Akebia Prices Public Offering of Common Stock Jan 06 2016
Akebia Plans to Raise Capital in Most Recent Proposed Offering Jan 05 2016
Akebia Therapeutics Lower Following Announcement Of Public Offering, Corporate And Clinical... Jan 05 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Jan 05 2016
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 04 2016
Akebia Therapeutics Announces Proposed Public Offering of Common Stock Jan 04 2016
Akebia Initiates Phase 3 PRO2TECT™ Program Jan 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK